Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial

Brenna McDonald, Laura A. Flashman, David B. Arciniegas, Robert J. Ferguson, Li Xing, Jaroslaw Harezlak, Gwen C. Sprehn, Flora Hammond, Arthur C. Maerlender, Carrie L. Kruck, Karen L. Gillock, Kim Frey, Rachel N. Wall, Andrew Saykin, Thomas W. McAllister

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The purpose of this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and without pharmacological enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at least 4 months before study enrollment with either objective cognitive deficits or subjective cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). Assessments were conducted pre-treatment (baseline) and after 6 weeks of treatment (post treatment). Outcome measures included scores on neuropsychological measures and subjective rating scales. Statistical analyses used linear regression models to predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant covariates. Statistically significant (P<0.05) treatment-related improvements in cognitive functioning were found for word-list learning (MAAT/placebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and working memory, and executive functioning after TBI.Neuropsychopharmacology advance online publication, 5 April 2017; doi:10.1038/npp.2016.261.

Original languageEnglish (US)
JournalNeuropsychopharmacology
DOIs
StateAccepted/In press - Apr 5 2017

Fingerprint

Neurobehavioral Manifestations
Methylphenidate
Randomized Controlled Trials
Placebos
Traumatic Brain Injury
Short-Term Memory
Linear Models
Therapeutics
Rehabilitation
Learning
Episodic Memory

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury : A Randomized, Placebo-Controlled Trial. / McDonald, Brenna; Flashman, Laura A.; Arciniegas, David B.; Ferguson, Robert J.; Xing, Li; Harezlak, Jaroslaw; Sprehn, Gwen C.; Hammond, Flora; Maerlender, Arthur C.; Kruck, Carrie L.; Gillock, Karen L.; Frey, Kim; Wall, Rachel N.; Saykin, Andrew; McAllister, Thomas W.

In: Neuropsychopharmacology, 05.04.2017.

Research output: Contribution to journalArticle

McDonald, Brenna ; Flashman, Laura A. ; Arciniegas, David B. ; Ferguson, Robert J. ; Xing, Li ; Harezlak, Jaroslaw ; Sprehn, Gwen C. ; Hammond, Flora ; Maerlender, Arthur C. ; Kruck, Carrie L. ; Gillock, Karen L. ; Frey, Kim ; Wall, Rachel N. ; Saykin, Andrew ; McAllister, Thomas W. / Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury : A Randomized, Placebo-Controlled Trial. In: Neuropsychopharmacology. 2017.
@article{51f19712f1294a69bc939470fc21f568,
title = "Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial",
abstract = "The purpose of this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and without pharmacological enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at least 4 months before study enrollment with either objective cognitive deficits or subjective cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). Assessments were conducted pre-treatment (baseline) and after 6 weeks of treatment (post treatment). Outcome measures included scores on neuropsychological measures and subjective rating scales. Statistical analyses used linear regression models to predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant covariates. Statistically significant (P<0.05) treatment-related improvements in cognitive functioning were found for word-list learning (MAAT/placebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and working memory, and executive functioning after TBI.Neuropsychopharmacology advance online publication, 5 April 2017; doi:10.1038/npp.2016.261.",
author = "Brenna McDonald and Flashman, {Laura A.} and Arciniegas, {David B.} and Ferguson, {Robert J.} and Li Xing and Jaroslaw Harezlak and Sprehn, {Gwen C.} and Flora Hammond and Maerlender, {Arthur C.} and Kruck, {Carrie L.} and Gillock, {Karen L.} and Kim Frey and Wall, {Rachel N.} and Andrew Saykin and McAllister, {Thomas W.}",
year = "2017",
month = "4",
day = "5",
doi = "10.1038/npp.2016.261",
language = "English (US)",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury

T2 - A Randomized, Placebo-Controlled Trial

AU - McDonald, Brenna

AU - Flashman, Laura A.

AU - Arciniegas, David B.

AU - Ferguson, Robert J.

AU - Xing, Li

AU - Harezlak, Jaroslaw

AU - Sprehn, Gwen C.

AU - Hammond, Flora

AU - Maerlender, Arthur C.

AU - Kruck, Carrie L.

AU - Gillock, Karen L.

AU - Frey, Kim

AU - Wall, Rachel N.

AU - Saykin, Andrew

AU - McAllister, Thomas W.

PY - 2017/4/5

Y1 - 2017/4/5

N2 - The purpose of this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and without pharmacological enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at least 4 months before study enrollment with either objective cognitive deficits or subjective cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). Assessments were conducted pre-treatment (baseline) and after 6 weeks of treatment (post treatment). Outcome measures included scores on neuropsychological measures and subjective rating scales. Statistical analyses used linear regression models to predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant covariates. Statistically significant (P<0.05) treatment-related improvements in cognitive functioning were found for word-list learning (MAAT/placebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and working memory, and executive functioning after TBI.Neuropsychopharmacology advance online publication, 5 April 2017; doi:10.1038/npp.2016.261.

AB - The purpose of this multicenter, prospective, randomized, placebo-controlled study was to evaluate and compare the efficacy of two cognitive rehabilitation interventions (Memory and Attention Adaptation Training (MAAT) and Attention Builders Training (ABT)), with and without pharmacological enhancement (ie, with methylphenidate (MPH) or placebo), for treating persistent cognitive problems after traumatic brain injury (TBI). Adults with a history of TBI at least 4 months before study enrollment with either objective cognitive deficits or subjective cognitive complaints were randomized to receive MPH or placebo and MAAT or ABT, yielding four treatment combinations: MAAT/MPH (N=17), ABT/MPH (N=19), MAAT/placebo (N=17), and ABT/placebo (N=18). Assessments were conducted pre-treatment (baseline) and after 6 weeks of treatment (post treatment). Outcome measures included scores on neuropsychological measures and subjective rating scales. Statistical analyses used linear regression models to predict post-treatment scores for each outcome variable by treatment type, adjusting for relevant covariates. Statistically significant (P<0.05) treatment-related improvements in cognitive functioning were found for word-list learning (MAAT/placebo>ABT/placebo), nonverbal learning (MAAT/MPH>MAAT/placebo and MAAT/MPH>ABT/MPH), and auditory working memory and divided attention (MAAT/MPH>ABT/MPH). These results suggest that combined treatment with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention, episodic and working memory, and executive functioning after TBI.Neuropsychopharmacology advance online publication, 5 April 2017; doi:10.1038/npp.2016.261.

UR - http://www.scopus.com/inward/record.url?scp=85017103260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017103260&partnerID=8YFLogxK

U2 - 10.1038/npp.2016.261

DO - 10.1038/npp.2016.261

M3 - Article

C2 - 27874023

AN - SCOPUS:85017103260

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -